| Name | di-Pal-MTO |
|---|
| Description | di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer drug mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Delivery of Mcl-1-specific anticancer siRNA (siMcl-1) using nanoparticles of mono-Pal-MTO and di-Pal-MTO (md11-Pal-MTO) in a 1:1 molar ratio enhances in vitro antitumour activity, reducing tumour cell viability by 81% and tumour size by 83%. Lipofectamine 2000-mediated transfection with siMcl-1 reduces tumour cell viability by 68%[1]. |
| References |
| Molecular Formula | C54H84N4O8 |
|---|---|
| Molecular Weight | 917.27 |